The invention relates to the field of biomedicine, and an anti-pertussis toxin (PT) single domain antibody and derivative protein thereof are disclosed. Specifically, a pertussis toxin-binding protein and use thereof are disclosed.

The present invention provides methods for enhancing the efficacy and/or safety of a vaccine. In certain embodiments, the invention provides methods to increase or potentiate the immune response to a vaccine in a subject in need thereof. The methods of the present invention comprise administering to a subject in need thereof an interleukin-4 receptor (IL-4R) antagonist such as an anti-IL-4R antibody in combination with said vaccine. In certain embodiments, the methods of the present invention are used to afford enhanced protection to an infectious disease such as whooping cough.

The present invention relates, in part, to modified humanized antibodies which bind the pertussis toxin protein and their use as therapeutic agents. In particular, the present invention is directed, in part, to improved humanized 1B7 and 11E6 antibodies with extended in vivo half-lives.

Compositions and methods for the detection and diagnosis of Bordetella pertussis are disclosed. Provided are antibodies, or antigen binding fragment thereof, specific for tracheal colonization factor A (TcfA). Also provided are compositions comprising an anti-TcfA antibody of the instant invention and a carrier; and methods for inhibiting, treating, and/or preventing pertussis and/or a B. pertussis infection in a subject in need thereof are provided, comprising administering an anti-TcfA antibody of the instant invention to the subject.

Compositions and methods for the detection and diagnosis of Bordetella pertussis are disclosed. Provided are antibodies, or antigen binding fragment thereof, specific for tracheal colonization factor A (TcfA). Also provided are compositions comprising an anti-TcfA antibody of the instant invention and a carrier; and methods for inhibiting, treating, and/or preventing pertussis and/or a B. pertussis infection in a subject in need thereof are provided, comprising administering an anti-TcfA antibody of the instant invention to the subject.

The present invention relates, in part, to bispecific antibodies that bind the pertussis toxin protein. The present invention further relates to the use of the bispecific antibodies for the prevention and treatment of Bordetella pertussis infections.

Compositions and methods for the detection of Bordetella pertussis and diagnosing pertussis are disclosed.

The present invention provides methods for enhancing the efficacy and/or safety of a vaccine. In certain embodiments, the invention provides methods to increase or potentiate the immune response to a vaccine in a subject in need thereof. The methods of the present invention comprise administering to a subject in need thereof an interleukin-4 receptor (IL-4R) antagonist such as an anti-IL-4R antibody in combination with said vaccine. In certain embodiments, the methods of the present invention are used to afford enhanced protection to an infectious disease such as whooping cough.

Systems and methods to link CD40 signaling to antigen binding, independently of CD40 ligand binding are described. The systems and methods include fusion proteins including an extracellular antigen binding domain linked to an intracellular CD40 signaling domain.

A method of immunizing a mammalian patient against infection by a bacterial pathogen involves administering a pertussis or Pseudomonas antigen to the mammalian patient. The pertussis antigen is least one of a chaperonin protein GroEL from Bordetella pertussis, or a fragment thereof; and an OmpA protein of Bordetella pertussis, or a fragment thereof. The Pseudomonas antigen is least one of a chaperonin protein GroEL from Pseudomonas aeruginosa, or a fragment thereof; and an OprF protein from Pseudomonas aeruginosa, or an OmpA-domain fragment thereof. The bacterial pathogen expresses a protein having at least 45% identity to the pertussis antigen. The bacterial pathogen may be a gram-negative bacteria. The bacterial pathogen may be a bacteria from a genus Escherichia, a genus Enterococcus, a genus Staphylococcus, a genus Klebsiella, a genus Acinetobacter, and a genus Enterobacter.